Health economic analysis of patients treated with isavuconazole in a German comprehensive cancer centre.

Abstract

BACKGROUND:

Invasive fungal diseases (IFD) are life-threatening and demand timely and appropriate treatment. Research showed that isavuconazole treatment positively affects clinical outcome and length of hospital stay (LOS).

OBJECTIVES:

The aim of this study was to assess the hospital costs of patients diagnosed with IFD and treated with isavuconazole using real-world data from a German cancer centre.

PATIENTS/METHODS:

Data and LOS collected from Jan-2016 to Jun-2021 at Department I of Internal Medicine, University Hospital Cologne were retrieved. Case-related resources consumed during the hospital stay across isavuconazole routes of administration (oral, parenteral, and mixed administration) were identified, quantified, valued and compared via a cost analysis that adopted the healthcare payer perspective.

RESULTS:

In total, 101 cases with isavuconazole treatment were identified (oral: n = 22, 21.8%; parenteral: n = 59, 58.4%; mixed: n = 20, 19.8%). Median total LOS was greater in the mixed group (46.5 days; p = .009). Median ICU LOS and ventilation duration were both longest in the parenteral-only group (16 days, p = .008; 224 h, p = .003). Invasive aspergillosis was the most frequent isavuconazole indication (n = 86, 85.2%). Average hospital costs were highest in the mixed group (€ 101,226). The median overall costs of cases treated with isavuconazole was € 52,050.

CONCLUSIONS:

Treating IFD is resource intensive, often requires intensive care and implies high rates of in-hospital mortality. Our study emphasises the high hospital treatment costs and thus the need for reimbursement systems to enable live-saving costly treatments.

• Authors: Julia Jeck, Sebastian M Wingen-Heimann, Florian Jakobs, Anna Kron, Jennifer Franz, Oliver A Cornely, Florian Kron
• Journal: Mycoses (Mycoses) Vol. 66 Issue 5 Pg. 405-411 (May 2023) ISSN: 1439-0507 [Electronic] Germany
• PMID: 36670539 (Publication Type: Journal Article)
• Copyright: © 2023 The Authors. Mycoses published by Wiley-VCH GmbH.

Chemical References

• isavuconazole
• Antifungal Agents
• Triazoles
• Nitriles

Topics

• Humans
• Antifungal Agents (therapeutic use)
• Neoplasms (complications, drug therapy)
• Triazoles (therapeutic use)
• Aspergillosis
• Nitriles (therapeutic use)
• Invasive Fungal Infections (drug therapy, microbiology)